318 related articles for article (PubMed ID: 1377948)
1. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
Boudet F; Girard M; Theze J; Zouali M
Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
[TBL] [Abstract][Full Text] [Related]
2. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
Boudet F; Keller H; Kieny MP; Thèze J
Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
[TBL] [Abstract][Full Text] [Related]
4. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
6. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
[TBL] [Abstract][Full Text] [Related]
7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
8. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
9. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
Kim YB; Han DP; Cao C; Cho MW
Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
[TBL] [Abstract][Full Text] [Related]
11. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
12. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
Javaherian K; Langlois AJ; LaRosa GJ; Profy AT; Bolognesi DP; Herlihy WC; Putney SD; Matthews TJ
Science; 1990 Dec; 250(4987):1590-3. PubMed ID: 1703322
[TBL] [Abstract][Full Text] [Related]
14. [Peptides from the principal neutralizing and CD4-binding domain: similar immunoreactive properties and structure pattern].
Meshcheriakova DV; Andreev SM; Sidorova MV; Vafina MG; Az'muko AA; Petrukhina AO; Khaitov RM
Vestn Ross Akad Med Nauk; 1992; (9-10):47-52. PubMed ID: 1283721
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
16. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
[TBL] [Abstract][Full Text] [Related]
17. Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential.
Fontenot JD; VanCott TC; Parekh BS; Pau CP; George JR; Birx DL; Zolla-Pazner S; Gorny MK; Gatewood JM
AIDS; 1995 Oct; 9(10):1121-9. PubMed ID: 8519447
[TBL] [Abstract][Full Text] [Related]
18. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
Laisney IL; Strosberg AD
Immunol Lett; 1999 Apr; 67(3):185-92. PubMed ID: 10369125
[TBL] [Abstract][Full Text] [Related]
19. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
[TBL] [Abstract][Full Text] [Related]
20. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
